DGIdb - NPM1 Gene Record

NPM1 4869 Druggable GenomeClinically ActionableDrug Resistance

Alternate Names:

4869
NUCLEOPHOSMIN 1
NPM1
B23
NPM
164040
7910
ENSG00000181163
OTTHUMG00000130465
35
PA31712
Nucleophosmin
T45591

Gene Info:

Gene Biotype	PROTEIN_CODING

(8 More Sources)

Gene Categories: Category Details

DNA REPAIR
DRUG RESISTANCE
DRUGGABLE GENOME
CLINICALLY ACTIONABLE

Publications:

Christensen et al., 2007, Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma., Mol. Cancer Ther.
Amin et al., 2016, TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors., Oncotarget
Zdzalik et al., 2014, Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma., J. Cancer Res. Clin. Oncol.
Mologni et al., 2015, NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922., Oncotarget
Ceccon et al., 2015, Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma., Mol. Cancer Res.
Wang et al., 2014, Nontoxic-dose of deguelin induce NPMc+ AML cell differentiation by selectively targeting Mt NPM1/SIRT1 instead of HDAC1/3., Curr Cancer Drug Targets
Yi et al., 2015, Deguelin, a selective silencer of the NPM1 mutant, potentiates apoptosis and induces differentiation in AML cells carrying the NPM1 mutation., Ann. Hematol.
Balusu et al., 2011, Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1., Blood
Burnett et al., 2010, The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA., Blood
Yee et al., 2016, A phase I trial of the aurora kinase inhibitor, ENMD-2076, in patients with relapsed or refractory acute myeloid leukemia or chronic myelomonocytic leukemia., Invest New Drugs
Garcia et al., 2016, Selective Toxicity of Investigational Ixazomib for Human Leukemia Cells Expressing Mutant Cytoplasmic NPM1: Role of Reactive Oxygen Species., Clin. Cancer Res.
Ardini et al., 2016, Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications., Mol. Cancer Ther.
Zhang et al., 2016, The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models., Clin. Cancer Res.

ASP-3026 NPM1

Interaction Score: 4.42

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type anaplastic large cell lymphoma

Response Type resistant

Approval Status Preclinical

PMIDs:
27009859 25749034 25421750

Sources:
JAX-CKB
IXAZOMIB NPM1

Interaction Score: 4.42

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type acute myeloid leukemia

Response Type predicted – sensitive

Approval Status Clinical Study

PMIDs:
26634271

Sources:
JAX-CKB
CHEMBL3397300 NPM1

Interaction Score: 3.68

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type anaplastic large cell lymphoma

Response Type resistant

Approval Status Preclinical

PMIDs:
27009859 25749034 25421750 27780853

Sources:
JAX-CKB
ALECTINIB NPM1

Interaction Score: 2.52

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type anaplastic large cell lymphoma

Response Type decreased response

Approval Status Preclinical

PMIDs:
27009859 25749034 25421750

Sources:
JAX-CKB
DEGUELIN NPM1

Interaction Score: 1.89

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type acute myeloid leukemia

Response Type sensitive

Approval Status Preclinical

PMIDs:
25348016 25242579

Sources:
JAX-CKB
CERITINIB NPM1

Interaction Score: 1.61

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type anaplastic large cell lymphoma

Response Type resistant

Approval Status Preclinical

PMIDs:
27009859 25749034 25421750

Sources:
JAX-CKB
LORLATINIB NPM1

Interaction Score: 1.47

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type Advanced Solid Tumor

Response Type resistant

Approval Status Preclinical

PMIDs:
25749034

Sources:
JAX-CKB
CRIZOTINIB NPM1

Interaction Score: 1.47

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type anaplastic large cell lymphoma

Response Type resistant

Approval Status Preclinical

PMIDs:
18089725 27009859 24509625 25749034 25421750

Sources:
JAX-CKB
VENETOCLAX NPM1

Interaction Score: 0.8

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB FDA
TRETINOIN NPM1

Interaction Score: 0.46

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21719597 19965647

Sources:
CIViC
ENMD-2076 NPM1

Interaction Score: 0.37

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type acute myeloid leukemia

Response Type sensitive

Approval Status Phase I

PMIDs:
27406088

Sources:
JAX-CKB
MIDOSTAURIN NPM1

Interaction Score: 0.35

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB FDA
VORINOSTAT NPM1

Interaction Score: 0.19

Interaction Types & Directionality:

n/a

Interaction Info:

Response Type sensitive

combination therapy Ixazomib + Vorinostat

Indication/Tumor Type acute myeloid leukemia

PMIDs:
26634271

Sources:
JAX-CKB
ENTRECTINIB NPM1

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type anaplastic large cell lymphoma

Response Type sensitive

Approval Status Preclinical

PMIDs:
26939704

Sources:
JAX-CKB

Ensembl: ENSG00000181163
- Version: 101_38
Alternate Names:

NPM1 Ensembl Gene Name

Gene Info:

Gene Biotype PROTEIN_CODING

Publications:

JAX-CKB: NPM1

Version: 27-September-2017

Alternate Names:

4869 CKB Entrez Id

NPM1 CKB Gene Synonym

B23 CKB Gene Synonym

Gene Info:

Publications:

Amin et al., 2016, TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors., Oncotarget

Mologni et al., 2015, NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922., Oncotarget

Zdzalik et al., 2014, Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma., J. Cancer Res. Clin. Oncol.

CIViC: NPM1

Version: 14-September-2020

Alternate Names:

4869 Entrez Gene ID

35 CIViC Gene ID

Gene Info:

Gene Categories:

DRUG RESISTANCE

Publications:

Balusu et al., 2011, Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1., Blood

Burnett et al., 2010, The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA., Blood

HingoraniCasas: ENSG00000181163
- Version: 31-May-2017
Alternate Names:

ENSG00000181163 Gene Symbol

NPM1 Ensembl Id

Gene Info:

Gene Categories:

DRUGGABLE GENOME

Publications:
PharmGKB: NPM1
- Version: 18-August-2020
Alternate Names:

PA31712 PharmGKB ID

Gene Info:

Publications:
GO: NPM1
- Version: 01-February-2022
Alternate Names:

NPM GO Gene Synonym

Gene Info:

Gene Categories:

DNA REPAIR

Publications:
Tempus: NPM1
- Version: 11-November-2018
Alternate Names:

NPM1 Gene Symbol

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
TTD: Nucleophosmin
- Version: 2020.06.01
Alternate Names:

NPM1 TTD Gene Abbreviation

T45591 TTD Target ID

Gene Info:

Publications:
MskImpact: NPM1
- Version: May-2015
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
FoundationOneGenes: NPM1
- Version: 03-September-2020
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
CarisMolecularIntelligence: NPM1
- Version: 04-September-2020
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
FDA: NPM1
- Version: 04-September-2020
Alternate Names:

Gene Info:

Publications:

Indication/Tumor Type	anaplastic large cell lymphoma
Response Type	resistant
Approval Status	Preclinical

Indication/Tumor Type	acute myeloid leukemia
Response Type	predicted – sensitive
Approval Status	Clinical Study

Indication/Tumor Type	Advanced Solid Tumor
Response Type	resistant
Approval Status	Preclinical

Response Type	sensitive
combination therapy	Ixazomib + Vorinostat
Indication/Tumor Type	acute myeloid leukemia

NPM1 Gene Record

NPM1 4869 Druggable GenomeClinically ActionableDrug Resistance

Alternate Names:

Gene Info:

Gene Categories: Category Details

Publications:

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type anaplastic large cell lymphoma Response Type resistant Approval Status Preclinical

PMIDs: 27009859 25749034 25421750

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type acute myeloid leukemia Response Type predicted – sensitive Approval Status Clinical Study

PMIDs: 26634271

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type anaplastic large cell lymphoma Response Type resistant Approval Status Preclinical

PMIDs: 27009859 25749034 25421750 27780853

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type anaplastic large cell lymphoma Response Type decreased response Approval Status Preclinical

PMIDs: 27009859 25749034 25421750

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type acute myeloid leukemia Response Type sensitive Approval Status Preclinical

PMIDs: 25348016 25242579

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type anaplastic large cell lymphoma Response Type resistant Approval Status Preclinical

PMIDs: 27009859 25749034 25421750

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type Advanced Solid Tumor Response Type resistant Approval Status Preclinical

PMIDs: 25749034

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type anaplastic large cell lymphoma Response Type resistant Approval Status Preclinical

PMIDs: 18089725 27009859 24509625 25749034 25421750

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB FDA

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21719597 19965647

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type acute myeloid leukemia Response Type sensitive Approval Status Phase I

PMIDs: 27406088

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB FDA

Interaction Types & Directionality: n/a

Interaction Info: Response Type sensitive combination therapy Ixazomib + Vorinostat Indication/Tumor Type acute myeloid leukemia

PMIDs: 26634271

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type anaplastic large cell lymphoma Response Type sensitive Approval Status Preclinical

PMIDs: 26939704

Sources: JAX-CKB

Ensembl: ENSG00000181163

Alternate Names: NPM1 Ensembl Gene Name

Gene Info: Gene Biotype PROTEIN_CODING

Publications:

JAX-CKB: NPM1

Alternate Names: 4869 CKB Entrez Id NPM1 CKB Gene Synonym B23 CKB Gene Synonym

Gene Info:

CIViC: NPM1

Alternate Names: 4869 Entrez Gene ID 35 CIViC Gene ID

Gene Info:

Gene Categories: DRUG RESISTANCE

HingoraniCasas: ENSG00000181163

Alternate Names: ENSG00000181163 Gene Symbol NPM1 Ensembl Id

Gene Info:

Gene Categories: DRUGGABLE GENOME

Publications:

PharmGKB: NPM1

Alternate Names: PA31712 PharmGKB ID

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type anaplastic large cell lymphoma

Response Type resistant

Approval Status Preclinical

PMIDs:
27009859 25749034 25421750

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type acute myeloid leukemia

Response Type predicted – sensitive

Approval Status Clinical Study

PMIDs:
26634271

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type anaplastic large cell lymphoma

Response Type resistant

Approval Status Preclinical

PMIDs:
27009859 25749034 25421750 27780853

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type anaplastic large cell lymphoma

Response Type decreased response

Approval Status Preclinical

PMIDs:
27009859 25749034 25421750

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type acute myeloid leukemia

Response Type sensitive

Approval Status Preclinical

PMIDs:
25348016 25242579

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type anaplastic large cell lymphoma

Response Type resistant

Approval Status Preclinical

PMIDs:
27009859 25749034 25421750

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type Advanced Solid Tumor

Response Type resistant

Approval Status Preclinical

PMIDs:
25749034

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type anaplastic large cell lymphoma

Response Type resistant

Approval Status Preclinical

PMIDs:
18089725 27009859 24509625 25749034 25421750

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB FDA

Interaction Types & Directionality:

n/a

PMIDs:
21719597 19965647

Sources:
CIViC

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type acute myeloid leukemia

Response Type sensitive

Approval Status Phase I

PMIDs:
27406088

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB FDA

Interaction Types & Directionality:

n/a

Interaction Info:

Response Type sensitive

combination therapy Ixazomib + Vorinostat

Indication/Tumor Type acute myeloid leukemia

PMIDs:
26634271

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type anaplastic large cell lymphoma

Response Type sensitive

Approval Status Preclinical

PMIDs:
26939704

Sources:
JAX-CKB

Alternate Names:

NPM1 Ensembl Gene Name

Gene Info:

Gene Biotype PROTEIN_CODING

Alternate Names:

4869 CKB Entrez Id

NPM1 CKB Gene Synonym

B23 CKB Gene Synonym

Alternate Names:

4869 Entrez Gene ID

35 CIViC Gene ID

Gene Categories:

DRUG RESISTANCE

Alternate Names:

ENSG00000181163 Gene Symbol

NPM1 Ensembl Id

Gene Categories:

DRUGGABLE GENOME

Alternate Names:

PA31712 PharmGKB ID

Alternate Names:

NPM GO Gene Synonym

Gene Categories:

DNA REPAIR

Alternate Names:

NPM1 Gene Symbol

Gene Categories:

CLINICALLY ACTIONABLE

Alternate Names:

NPM1 TTD Gene Abbreviation

T45591 TTD Target ID

Gene Categories:

CLINICALLY ACTIONABLE

Gene Categories:

CLINICALLY ACTIONABLE

Gene Categories:

CLINICALLY ACTIONABLE